• Uwe Zeymer, Karl Werdan, Gerhard Schuler, Ralf Zahn, Franz-Josef Neumann, Georg Fürnau, Suzanne de Waha, Steffen Schneider, and Holger Thiele.
• 1 Klinikum Ludwigshafen, Medizinische Klinik B, Germany.
• Eur Heart J Acute Cardiovasc Care. 2017 Oct 1; 6 (7): 601-609.

BackgroundCurrent guidelines recommend immediate multivessel percutaneous coronary intervention (PCI) in patients with cardiogenic shock, despite the lack of randomised trials. We sought to investigate the use and impact on outcome of multivessel PCI in comparison to culprit lesion only PCI in a retrospective analysis in patients with cardiogenic shock complicating acute myocardial infarction.Methods And ResultsIn the randomised IABP-SHOCK II trial, investigating the effect of intra-aortic balloon pump on outcome, 451 (75%) of the total of 600 patients had multivessel coronary artery disease and underwent PCI. Immediate multivessel PCI was performed in 167 (37%) patients. TIMI 3 patency after PCI in all treated vessels was observed in 83.2% versus 79.0% of patients after multivessel versus culprit lesion PCI, respectively. The 30-day (44.9% vs. 42.3%) and 12-month (54.8% vs. 52.7%) mortality rates did not significantly differ between the two groups. In the multivariate analysis multivessel PCI was not associated with an improved mortality after 12 months (odds ratio 0.92, 95% confidence intervals 0.69-1.21).ConclusionIn this retrospective analysis of the largest randomised study in cardiogenic shock immediate multivessel PCI was used in approximately one third of patients with cardiogenic shock. There was no benefit with immediate multivessel PCI in comparison to culprit lesion only PCI. Therefore a randomised trial is needed to determine the definitive role of multivessel PCI in cardiogenic shock.Clinical Trial RegistrationClinicalTrials.gov , NCT00491036.

36 keywords...

hide…